Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Reflections on the AGM

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on May 17, 2024 1:33pm

90 Views

Post# 36045883

RE:RE:Reflections on the AGM

Well said, ONCInvestor.

Sadly, MC has stacked the BOD, and they are all feeding from the same trough, so it seems very unlikely that either he or his good friend Kirk will ever be fired.

Most likely, they both get large bonuses and another boatload of options at the end of 2024 after leading ONC through yet another "outstanding" year of amazing progress.

How unfortunate that every corporate presentation can be prefaced with a disclaimer about "forward-looking statements" that then gives MC free rein to overpromise and make exuberant claims about pending trials that never materialize.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland